Bioline Launches New JetSeq DNA Quantification Kits
(Thomson Reuters ONE) -
CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a
wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today
announced the further expansion of the JetSeq(TM) portfolio for Next Generation
Sequencing (NGS) sample preparation.
The new JetSeq(TM) Library Quantification Kit is a qPCR-based assay that
provides fast, accurate and sensitive quantification of adaptor-ligated DNA
fragments during the preparation of Illumina compatible NGS libraries. The
JetSeq(TM) Library Quantification Kit relies on SYBR(®1) Green I for detection
and contains all of the components required for library quantification,
including dilution buffer, P5 and P7 adapter primers and six pre-diluted DNA
standards to minimize pipetting, reduce variability and thereby increase
reproducibility. The kit has sufficient standards to quantify eighteen libraries
on individual plates or up to seventy-six libraries when multiple libraries are
quantified on the same plate.
Marco Calzavara, President of Bioline commented, "The release of the new
JetSeq(TM) Library Quantification Kit compliments the JetSeq(TM) Library
preparation kits that Bioline launched last month, moving us even further into
the NGS space. The kit builds on our extensive knowledge in qPCR, providing a
fast, sensitive and reliable solution to determine library concentrations,
giving customers confidence in the cluster density loaded on Illumina sequencing
platforms."
Richard L. Eberly, President, Chief Commercial Officer, stated, "We are pleased
to announce the release of the new JetSeq(TM) Library Quantification Kit; this
is an important addition to our ever-increasing portfolio of NGS products and
gives our life science customers greater confidence in the quantification of
their sequencing libraries. The further development of the JetSeq(TM) family
shows our commitment, not just to the continued development and expansion of
products from Bioline, but also to our customers, giving them a greater support
around this fast-growing market."
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures,
markets and distributes a broad range of innovative diagnostic test kits, rare
reagents, specialty biologicals and components. Utilizing a variety of methods,
our diagnostic tests provide accuracy, simplicity and speed in the early
diagnosis and treatment of common medical conditions, such as infections and
lead poisoning. Meridian's diagnostic products are used outside of the human
body and require little or no special equipment. The Company's diagnostic
products are designed to enhance patient well-being while reducing the total
outcome costs of health care. Meridian has strong market positions in the areas
of gastrointestinal and upper respiratory infections and blood lead level
testing. In addition, Meridian is a supplier of rare reagents, specialty
biologicals and components used by organizations in the life science and agribio
industries engaged in research and by companies as components in the manufacture
of diagnostics. The Company markets its products and technologies to hospitals,
reference laboratories, research centers, diagnostics manufacturers and agribio
companies in more than 70 countries around the world. The Company's shares are
traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website
address is www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:
For more information about Bioline, please visit http://www.bioline.com.
(1) SYBR is a registered trademark of Thermo Fisher Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly(at)meridianbioscience.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meridian Bioscience, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="BonTerra Closes $5.2M Strategic Investment by Kinross Gold
Datum: 27.03.2017 - 16:32 Uhr
Sprache: Deutsch
News-ID 532668
Anzahl Zeichen: 4560
contact information:
Town:
Cincinnati
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bioline Launches New JetSeq DNA Quantification Kits"
steht unter der journalistisch-redaktionellen Verantwortung von
Meridian Bioscience, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
